Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Six months ended June 30, 2001 (Second Quarter ended June 30, 2001)
Business Overview: The Company operates two primary segments: Healthcare Distribution (dental, medical, veterinary, and international) and Technology (practice management software). It distributes healthcare products and services to office-based practitioners primarily in North America and Europe.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2001 |
Six Months Ended June 24, 2000 |
Three Months Ended June 30, 2001 |
Three Months Ended June 24, 2000 |
|---|---|---|---|---|
| Net Sales | $1,200,180 | $1,122,770 | $606,285 | $568,631 |
| Gross Profit | $326,249 | $307,931 | $166,892 | $158,815 |
| Gross Margin | 27.2% | 27.4% | 27.5% | 27.9% |
| Operating Income | $62,855 | $54,459 | $35,272 | $30,982 |
| Net Income | $35,042 | $27,779 | $20,910 | $16,381 |
| Diluted EPS | $0.81 | $0.67 | $0.48 | $0.39 |
| Cash from Operations | $29,279 | $65,345 | N/A | N/A |
| Cash & Equivalents (End of Period) | $75,847 | $45,900 | N/A | N/A |
| Total Debt (Current + Long-term) | $264,512 | $276,693 | N/A | N/A |
Note: Debt figures include current maturities of long-term debt ($4,596) and long-term debt ($250,799) as of June 30, 2001.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6.9% ($77.4 million) for the six months ended June 30, 2001, compared to the prior year. The Healthcare Distribution segment drove 98.7% of this growth, led by a 15.8% increase in Medical sales and a 4.4% increase in Dental sales. International sales grew 0.5% despite unfavorable exchange rates; without currency effects, growth would have been 8.2%.
- Profitability: Operating income rose 15.4% to $62.9 million. However, gross profit margins declined slightly (27.2% vs. 27.4% prior year) due to sales mix changes in the distribution segment, though the Technology segment saw margin expansion to 72.0%.
- Cash Flow: Net cash provided by operating activities decreased significantly to $29.3 million from $65.3 million in the prior year. This was primarily due to a $49.8 million decrease in accounts payable and accruals, largely attributed to payments for year-end inventory buy-ins.
- Debt Reduction: Total debt decreased by approximately $12.2 million year-over-year, driven by principal payments on long-term debt and bank borrowings.
Outlook, Risks, and Management Commentary
- Capital Expenditures: Management expects to invest more than $45.0 million in capital projects during the fiscal year ending December 29, 2001, to modernize facilities and integrate operations.
- Liquidity: The Company maintains $75.8 million in cash and equivalents and has access to a $150.0 million revolving credit facility (unused) and subsidiary facilities totaling $43.2 million ($9.1 million utilized). Management believes liquidity is sufficient for foreseeable needs.
- Accounting Changes: The Company is assessing the impact of new FASB Statements No. 141 (Business Combinations) and No. 142 (Goodwill). Future acquisitions will use the purchase method, and goodwill will no longer be amortized but tested for impairment annually. The impact on financial position is currently undetermined.
- Legal Proceedings: The Company is a defendant in approximately 70 product liability cases, including 54 involving latex glove allergies and 9 involving "Phen/fen" drugs. It is also defending a class action lawsuit regarding practice management software (Easy Dental) in Texas, where the appeal on class certification is pending before the Texas Supreme Court. Management believes insurance covers these risks.
- Market Risks: Risks include foreign currency fluctuations, consolidation of healthcare practitioners, healthcare reform, and the competitive landscape of e-commerce.
Investor Verification Checklist
- Working Capital Trends: Verify the sustainability of the $49.8 million reduction in accounts payable and its impact on future operating cash flows.
- Legal Exposure: Monitor the status of the Texas Supreme Court appeal regarding the Easy Dental class action and the indemnification status of the latex glove and Phen/fen litigation.
- Accounting Impact: Track the Company's assessment of FAS 141 and FAS 142 adoption, specifically regarding the reclassification of intangible assets and the cessation of goodwill amortization.
- International Currency: Review the sensitivity of international sales to exchange rate fluctuations, as reported growth was masked by currency headwinds.
- Capital Allocation: Confirm the execution of the planned $45.0 million in capital expenditures and their expected return on investment.